Optimizing patient outcomes and empowering the patient-clinician partnership
Abstract
The treatment landscape for narcolepsy is rapidly evolving with the introduction of new therapies featuring unique mechanisms of action and innovative formulations of established treatments. The recent approval of a once-nightly sodium oxybate formulation (SO-ER) has expanded the spectrum of oxybate therapies to 3, including the traditional immediate-release formulation (OXB) and a low-sodium version containing calcium, magnesium, potassium, and sodium oxybates (LXB). While the availability of diverse options allows clinicians to tailor oxybate-based treatments, it also raises challenges in selecting and fine-tuning these therapies. Involving patients in the decision-making process through shared decision-making (SDM) platforms can be an effective approach to optimizing oxybate therapy. This review article aims to provide clinicians with a comprehensive overview of the unique characteristics of available oxybate formulations and potential strategies for delivering empathetic care that incorporates SDM into the selection and optimization of oxybate-based treatment regimens.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.